XML 37 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Investments
12 Months Ended
Mar. 31, 2021
Long-term Investments and Receivables, Net [Abstract]  
Long-term investments
11.
Long-term investments
The Company’s long-term investments consist of the following:
 
   
As of March 31,
   
As of March 31,
 
   
2020
   
2021
 
   
RMB
   
RMB
 
Equity method investments
   3,104    2,973 
Available-for-sale
investments
   70,328    71,357 
  
 
 
   
 
 
 
Total
   73,432    74,330 
  
 
 
   
 
 
 
Equity method investments
The Company applies equity method in accounting for its investments in entities in which the Company has the ability to exercise significant influence but does not have control. As of March 31, 2020 and 2021, the carrying value of the equity method investments were RMB3.1 million and RMB3.0 million respectively, the change of which primarily relates to the equity loss recognized.
Available-for-sale
debt investments
The following table summarizes the Company’s
available-for-sale
debt investments as of March 31, 2020:
 
   Cost   Gross unrealized gains   Gross unrealized losses   Fair value
Unlisted debt securities
   60,000    10,328    —     70,328
  
 
 
   
 
 
   
 
 
   
 
The following table summarizes the Company’s
available-for-sale
debt investments as of March 31, 2021:
 
   Cost   Gross unrealized gains   Gross unrealized losses   Fair value
Unlisted debt securities
   60,000    11,357    —     71,357
  
 
 
   
 
 
   
 
 
   
 
In October 2017, the Company purchased 7.2% shareholding of Qingdao Shuangan Biotechnology Co., Ltd (“Qingdao Shuangan”) with a cash consideration of RMB10 million. According to the investment agreement, the Company is entitled to demand redemption after 48 months from the transaction closing date. As of March 31, 2020 and 2021, based on the valuation results, the Company
re-measured
the investment in Qingdao Shuangan at fair value of RMB17 million and RMB17.3 million, respectively. For the years ended March 31, 2020 and 2021, the unrealized securities holding gain (net of tax) of RMB1.0 million and RMB0.02 million was recorded as other comprehensive income, respectively.
In October 2019, the Company purchased 23.64% shareholding of Beijing Petdog Technology Development Co., Ltd. (“Beijing Petdog”) with a cash consideration of RMB50 million. According to the investment agreement, the Company is entitled to demand redemption after 60 months from the transaction closing date. As of March 31, 2020 and 2021, based on the valuation results, the Company
re-measured
the investment at fair value of RMB53.3 million and RMB54.0 million, respectively. For year ended March 31, 2020 and 2021, the unrealized securities holding gain (net of tax) of RMB2.3 million and RMB0.75 million was recorded as other comprehensive income.